Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.50 | -0.27% | 1,300.00 | 11,318,577 | 16:35:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,301.50 | 1,302.50 | 1,310.00 | 1,299.50 | 1,306.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 10.96 | 54.03B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:37:46 | O | 1 | 1,302.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 19/11/2024 | 09:24 | ALNC |  GSK hails positive results for linerixibat in treating relentless itch |
| 19/11/2024 | 07:00 | UK RNS | GSK PLC GLISTEN Trial of Linerixibat Meets Endpoint |
| 14/11/2024 | 08:54 | ALNC | GSK hails survival results in blood cancer patients with Blenrep |
| 14/11/2024 | 07:00 | UK RNS | GSK PLC GSK announces overall survival results for Blenrep |
| 13/11/2024 | 15:00 | UK RNS | GSK PLC Block listing Interim Review |
| 12/11/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 11/11/2024 | 15:01 | UK RNS | GSK PLC GSK publishes provisional 2025 dividend dates |
| 04/11/2024 | 16:16 | ALNC | DIRECTOR DEALINGS: Drachs ups stake in Metals Exploration as CFO sells |
| 01/11/2024 | 15:00 | UK RNS | GSK PLC Total Voting Rights |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/11/2024 | 19:18 | Glaxosmithkline - The recovery | 33,764 |
| 15/11/2024 | 10:28 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 191 |
| 15/11/2024 | 10:22 | GSK | 73 |
| 10/10/2024 | 05:29 | GlazoSmithKline - News & Information | 148 |
| 17/4/2023 | 18:25 | Gsk zantac | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-11-20 19:09:18 | 1,306.50 | 4,240,788 | 55,405,895.22 | O |
| 2024-11-20 19:09:18 | 1,306.50 | 4,240,788 | 55,405,895.22 | O |
| 2024-11-20 19:08:57 | 1,306.50 | 4,240,788 | 55,405,895.22 | O |
| 2024-11-20 16:43:47 | 1,302.00 | 1 | 13.02 | O |
| 2024-11-20 16:39:35 | 1,306.50 | 1,650,879 | 21,568,734.14 | O |
| Top Posts |
|---|
Posted at 20/11/2024 08:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,303.50p.Gsk currently has 4,145,087,815 shares in issue. The market capitalisation of Gsk is £53,989,768,790. Gsk has a price to earnings ratio (PE ratio) of 10.96. This morning GSK shares opened at 1,306.50p |
Posted at 30/10/2024 18:53 by pj84 Positive update from HL"GSK: full-year guidance confirmed despite weak Q3 vaccine sales GSK beat Q3 earnings estimates due to growth in its specialty medicines. Written by Derren Nathan Head of Equity Research Oct 30, 2024 No recommendation Underlying operating profit rose by 5% to £2.8bn, driven by revenue growth and effective cost management. Underlying earnings per share also grew 5% to 49.7p, ahead of market forecasts of 43.5p. Free cash flow fell 20% to £1.3bn largely driven by the acquisition of rights to certain vaccine technologies. Net debt has fallen from £15.0bn to £12.8bn since the start of the year. GSK recognised a £1.8bn charge in relation to the Zantac settlement, with the ‘vast majority’ of cases now settled. With all full-year guidance unchanged, pointing to underlying operating profit growth in the 11-13% range. The third-quarter dividend rose from 14p to 15p. The shares were down 3.6% in early trading. Our view GSK’s on track to meet upgraded estimates despite ongoing weakness in it’s vaccine portfolio. Two key products, Arexvy and Shingrix were coming up against headwinds in the important US market. But both products still have the potential to reach new patient populations. The financial progress is underpinned by excellence in research & development that’s seen 11 positive late stage clinical updates so far this year, and is expected to yield five major product approvals next year. However, there can be no guarantee of continued success. Falling sales of COVID-19 medicines have held back growth but now that they are no longer material, comparatives are becoming less demanding. Beyond vaccines, the group also has a strong presence in HIV treatments which make up about 20% of total revenues. Its newer HIV treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments. But the group focus for HIV is shifting to long-acting innovation therapies. And it’s these that have helped capture additional market share and drive double-digit growth for the category in the first half. Apretude is another important product to watch in the space. It’s the only approved medicine in its class and real-world studies have shown it to be 99% effective at preventing HIV infections. Cancer treatment, although relatively small in terms of current sales, is growing rapidly. Recent approvals and launches in new markets mean there are strong growth drivers for the existing portfolio. The development pipeline looks promising. Net debt has been coming down and currently sits at under 1.3x forecast cash profits, which we don't see as a major concern. The strong financial position and improving cash generation helps support a prospective dividend yield of 4.4%, but remember, no future payouts to shareholders can be assured. GSK's valuation is below the long-term average, and significantly less demanding than many of its peers. One reason it’s been held back was uncertainty over the financial impact of alleged cancer links to its heartburn drug Zantac. News that the majority of lawsuits relating to were being settled for $2.2bn materially de-risks the investment case. Looking ahead, strong execution of the growth strategy and clinical pipeline is likely to be the key focus for shareholders moving forward. So far so good, but remember, the drug approval process is long and expensive, with many treatments never seeing the light of day." HL forecast the forward PE of 8.6 with a forecast dividend yield of 4.4% |
Posted at 11/10/2024 07:25 by geckotheglorious On a positive sideHargreaves: Buy GSK before Zantac discount goes GSK (GSK) is drawing a line under its Zantac litigation with a bumper payout which ‘substantially derisks’ the investment case, says Hargreaves Lansdown. Shares in the Citywire Elite Companies AAA-rated pharmaceutical giant climbed 3.2% to £15.05 yesterday after it confirmed it had paid $2.2bn to settle 80,000 cases in US courts over claims that a version of its heartburn treatment Zantac caused cancer. The payment covers 93% of claims but GSK accepts no wrongdoing. It will also pay $70m in a separate but related action. Analyst Derren Nathan said the outcome was ‘significantly better’ than expected, with some estimates as high as $45bn. ‘Looking ahead, GSK’s operational performance should be the key driver of investment,’ he said. ‘Execution has been impressive of late, with two upgrades already in the bag this year.’ It has faced headwinds in key vaccine programmes but overall, ‘recent clinical progress elsewhere in the portfolio has also seen a bigger share of successes than failures’. ‘The upcoming Zantac settlements substantially derisk the investment case for GSK shares which are trading at a hefty discount to the sector, meaning this could be an opportune time to consider increasing exposure to the stock,’ he said. |
Posted at 10/10/2024 15:41 by geckotheglorious GSK update eases investors’ fears as focus turns to vaccinesFTSE 100 pharmaceutical giant resolves legal case over Zantac drug as concern shifts to uptake of firm's key vaccines. Relief for GSK investors after the drugs giant moved to end two years of Zantac litigation uncertainty was today balanced by near-term worries over the uptake of key vaccines. GSK shares reached early afternoon 5% or 70p higher at 1528p, below the initial 10% uptick predicted by Jefferies analysts following last night’s disclosure. Jefferies said the settlement of 93% of Zantac liability cases for $2.2 billion is equivalent to about 40p a share and compared with its own $2 billion-$3.5 billion estimate. GSK, which admitted no liability, intends to fund the costs from existing financial resources and said there will be no impact on its “growth agenda or investment plans”. Its dividend policy for a payout equivalent to 40%-60% of earnings is unchanged, it told City analysts. Having noted higher previous product liability settlements in the pharma industry, UBS said the value of the GSK agreement should be a positive surprise to investors. It said: “We see the settlement as a clear positive, removing a major overhang and uncertainty for investors.” The bank pointed out that the remaining 7% of cases were outstanding because the company had chosen to approach the 10 largest plaintiff firms as a priority. The process is set to conclude by the end of the first half of 2025. Like counterparts at Jefferies, UBS warned that other factors may continue to hang over GSK’s valuation despite the removal of Zantac uncertainty. UBS said these near-term challenges included weak uptake for the respiratory syncytial virus (RSV) product Arexvy and increasing competition in long-acting HIV prevention. It also flagged slower-than-expected uptake of shingles vaccine Shingrix in China. Launched in the third quarter of 2023 and available in major retail pharmacies, Arexvy generated £244 million in sales in the first six months of the year. It had two-thirds of the retail vaccination share in the second quarter, but demand decreased overall in line with anticipated respiratory virus seasonality patterns. UBS has a Neutral stance and price target of 1,580p, while Jefferies had a price target of 2,000p prior to yesterday’s legal developments. The US bank said: “Concerns linger over sales expectations for RSV vaccine Arexvy in both the second half and 2025 given recent slow US RSV vaccine uptake and data supporting an every three year re-vaccination schedule. “In addition, investors continue to debate the sustainability of the Shingrix franchise, given US sales declines and potential concerns around uptake in China.” GSK is due to post third-quarter results on 30 October, having upgraded full-year guidance in July as new launches in oncology boosted sales growth in its Specialty Medicines division. Turnover is now expected to grow by between 7% and 9% and core earnings per share in the range of 10% and 12%. It recently paid a 15p a share quarterly dividend as part of plans to distribute 60p a share across the year. Shore Capital points out that shares trade on a forward looking multiple of 8.1 times, a significant discount to peers and below the 12 times that GSK has historically commanded. It believes shares deserve to be at 2,200p. Analyst Sean Conroy expects that the Zantac developments will serve as a clearing event for GSK and be broadly well received. He added: “This now provides an excellent opportunity for the shares to properly re-rate and allow people to refocus their attention on the improving growth outlook GSK has been delivering since the demerger of Haleon" |
Posted at 12/9/2024 06:16 by the grumpy old men Issued: 12 September 2024, London UKGSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme · A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults · mRNA platform elicits strong overall antibody titres with an acceptable safety profile · Data support progression to phase III clinical trials GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care. In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested. These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development. GSK's Chief Scientific Officer, Tony Wood said: "This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season." GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing. About study NCT06431607 The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine. |
Posted at 12/9/2024 06:15 by the grumpy old men Issued: 11 September 2024, London UKStatement: Zantac (ranitidine) litigation - Dixon case GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed. Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. |
Posted at 20/8/2024 08:07 by tradermichael This is better:GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer. Breakthrough therapy designation is given for drugs that have the potential to help treat serious conditions and where preliminary clinical evidence may indicate substantial improvement over currently available therapy. The drug, which currently goes by the name HS-20093 or the code GSK5764227, has shown promising early clinical evidence, the company said, in trials in China. It is being developed by Chinese biopharmaceutical company Hansoh Pharma for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumours. It is in multiple phase I and II clinical trials in China, with GSK's global Phase I trials for GSK5764227 set to begin in the second half of this year. GSK said results from the early-stage clinical trial will be presented at the 2024 World Conference on Lung Cancer taking place in early September and it plans to begin global phase-two trials in the second half of the year. GSK acquired exclusive worldwide rights for GSK5764227 from Hansoh earlier this year. |
Posted at 04/8/2024 13:23 by xtrmntr From the IC.At first sight, the market seemed to shrug off what were objectively decent results for drugmaker GSK (GSK) as the now pure play pharmaceutical company finds its feet and restocks what had become a threadbare research & development pipeline. Getting more value out of hard-to-copy medicines is a priority for GSK, and one where it lags its highly valued competitor AstraZeneca (AZN), but first it has a battalion of troubles to deal with. It is the state of litigation which has given investors a dyspeptic ulcer. The prospect of the company facing long rounds of litigation over its Zantac reflux medicine, with suits alleging its cancer-causing properties having been filed in numerous jurisdictions, was enough to crash the shares earlier this year the main problem being the currently unquantifiable cost of the saga.There is nothing new to report on this front, other than the company's legal costs in relation to this topic have increased, although it does not break these out of the cost of individual litigation.Unsurpris |
Posted at 02/8/2024 09:22 by davius Pick 'n' mix in the broker ratings today...Stifel raises GSK price target to 1,770 (1,740) pence - 'hold' DZ Bank cuts fair value for GSK to 1,650 (1,750) pence - 'hold' JPMorgan cuts GSK price target to 1,550 (1,660) pence - 'underweight' |
Posted at 23/7/2024 14:33 by tradermichael GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV. Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate. The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation". The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy. Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people. The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP. "The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said. Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI. ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184. "The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained. |
Posted at 05/7/2024 19:08 by xtrmntr It has been a turbulent few months for GSK (GSK) and its investors. The group hiked earnings guidance in May after a strong first quarter, only to see its shares tumble a few weeks later following an inauspicious ruling in the litigation cases relating to heartburn drug Zantac. Now it appears a revised recommendation from US health regulators will hurt sales of one of the company's key vaccines, Arexvy.The jab is designed to protect adults against RSV, a common respiratory virus that can cause serious illness in vulnerable individuals. Both Pfizer (US:PFE) and Moderna (US:MRNA) have produced competitor vaccines, although Arexvy was the first on the market. Last year, the Centers for Disease Control and Prevention (CDC) advised everyone over 60 to get immunised against RSV which was seemingly good news for market leader GSK.However, after reviewing the data, a CDC committee said vaccines should be restricted to the 75-plus cohort, with exceptions for 60-74 years olds with pre-existing conditions. "This move was characterised by one speaker as protecting 'the worried well' from any risks," said UBS analyst Jo Walton. "And if it turns out that re-boosting is not possible, [the decision] keeps the vaccine for use only when a patient is most likely to get a benefit."GSK had also hoped US health authorities would endorse Arexvy for 50-59-year-olds after a recent Food and Drug Administration (FDA) approval for this group. But no such support materialised. According to UBS, this means interested patients would probably have to self-fund their vaccinations at a list price of $300 (£236). Jabs that receive the CDC's seal of approval tend to receive some level of insurance coverage, meaning patients can access them at reduced rates.At present, there isn't enough data on Arexvy's durability for regulators to endorse booster doses and this is crucial for predicting future earnings. Once the results of ongoing trials are published, it's possible that the CDC could expand its recommendations to include vulnerable people in additional age brackets. Brokers are seemingly divided over the longer-term impact of last week's decision, with one Citi analyst stating peak sales of the jab would now "fall materially".Meanwhil |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
